| Identification | Back Directory | [Name]
Nelonicline | [CAS]
1026134-63-3 | [Synonyms]
ABT-126
Nelonicline
Nelonicline（ABT-126）
2-(((3R,4r,5S,7s)-1-azaadamantan-4-yl)oxy)-5-phenyl-1,3,4-thiadiazole
1-Azatricyclo[3.3.1.13,7]decane, 4-[(5-phenyl-1,3,4-thiadiazol-2-yl)oxy]-, stereoisomer | [Molecular Formula]
C17H19N3OS | [MDL Number]
MFCD27987904 | [MOL File]
1026134-63-3.mol | [Molecular Weight]
313.42 |
| Chemical Properties | Back Directory | [Boiling point ]
460.2±55.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
7.78±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease[1][2][3]. | [storage]
Store at -20°C | [References]
[1] Zhang D, et al. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015;30(14):1901-1911. DOI:10.1002/mds.26453
[2] Haig G, et al. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study. Neuropsychopharmacology. 2016;41(12):2893-2902. DOI:10.1038/npp.2016.101
[3] Gault LM, et al. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther. 2016;8(1):44. Published 2016 Oct 18. DOI:10.1186/s13195-016-0210-1 |
|
|